People with inflammatory bowel disease, like ulcerative colitis, are 2 to 3 times more likely to develop blood clots than ...

Phase 3b LUCENT-URGE is the first study in inflammatory bowel disease to assess bowel urgency across three measures — severity, frequency and stool deferral time — reflecting the spectrum of its ...

Building on 12-week findings, icotrokinra demonstrated clinically meaningful outcomes at Week 28 with 31.7% of patients achieving clinical remission and ...

Building on 12-week findings, icotrokinra demonstrated clinically meaningful outcomes at Week 28 with 31.7% of patients achieving clinical remission and 38.1% showing ...

Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) approved a single-injection, once-mo ...

SunRock Biopharma, a biotechnology company focused on developing next-generation therapeutic antibodies, and Chime Biologics, a global leading contract development and manufacturing organization (CDMO ...

Xencor, Inc. recently presented initial results from its Phase 1 dose-escalation study of XmAb819, an ENPP3 x CD3 bispecific antibody, in patients with advanced clear cell renal cell carcinoma at the ...

Johnson & Johnson announces positive week 28 results from phase 2b ANTHEM-UC study of icotrokinra in adults with moderately to severely active ulcerative colitis: Phoenix Tuesday, ...

Q3 2025 Earnings Call Transcript October 30, 2025 Insmed Incorporated misses on earnings expectations. Reported EPS is $-1.75 EPS, expectations were $-1.33. Operator: Thank you for standing by. My ...

A prospective population-based cohort study of suboptimally active adults (<8,000 steps per day) assessed whether individuals who accumulate their daily steps in shorter or longer bouts are at greater ...